Abstract: The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics.

Abstract: The present invention relates to an extended release pharmaceutical tablet composition comprising guanfacine comprising: a core containing guanfacine or a pharmaceutically acceptable salt thereof and one or more of pH-independent rate controlling polymer(s) and other pharmaceutically acceptable excipients; optionally a coating over the core as in (a) wherein, the coating comprises one or more of pH-independent rate controlling polymer(s).

Abstract: The present invention relates to uncoated modified-release tablets of lamotrigine and the process for preparation thereof, wherein the tablets comprise a portion of lamotrigine in an admixture with a pH-dependent polymer.

Abstract: The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof.

Abstract: The present invention relates to extended release tablets comprising a core which comprises of nisoldipine, a rate-controlling hydrophilic polymer and optionally, an enteric agent. Such tablets may also be coated with a release rate-controlling coating comprising of a hydrophobic polymer or enteric agent or combinations thereof, in particular ethylcellulose, and Eudragits.

Abstract: This invention relates to stabilized pharmaceutical compositions comprising atorvastatin or pharmaceutically acceptable salts thereof, and processes for the preparation of the same.

Abstract: The present invention relates to an oily suspension of atovaquone comprising atovaquone particles and a combination of surfactants having HLB more than 10.

Abstract: The present invention relates to an extended release dosage form of quetiapine wherein the dosage form comprises quetiapine and rate-controlling polymer selected from polyethylene oxide, sodium alginate and natural gum and combinations thereof. The dosage form may additionally comprise at least one water-insoluble polymer.

Abstract: A pharmaceutical composition of sirolimus comprising an inert core and a sugar overcoat, wherein said sugar overcoat comprises sirolimus, a poloxamer other than poloxamer 188, microcrystalline cellulose and binder has been developed.

Abstract: The present publication relates to a vacuum-sealed pack comprising an amorphous statin or a pharmaceutical composition thereof and at least one stabilizer such as, for example, an oxygen absorber, a moisture absorber or a combination thereof.

Abstract: Sirolimus particles having d90 value of from about 2? to about 10? have been developed. Further, pharmaceutical composition comprising sirolimus particles having d90 value of from about 2? to about 10? have also been developed.

Abstract: The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation.

Abstract: The present invention relates to solid oral dosage forms of ziprasidone and salts thereof and processes for their preparation, containing colloidal silicon dioxide.

Abstract: The present invention relates to enteric coated didanosine compositions having a subcoat comprising hydroxypropyl methylcellulose, and process for preparation thereof. The enteric coating ranges from 19-25% w/w of the composition. The compositions are stable and have acceptable acid resistance and release profile.

Abstract: The present invention relates to a nanodispersion composition comprising sirolimus and a surface modifier wherein effective average particle size of Sirolimus is more than 400 nm and process for preparation thereof.

Abstract: The present invention relates to stable solid dosage form and a dry process for preparing amorphous cefditoren pivoxil solid dosage forms and coating the solid dosage form with one or more layers of aqueous dispersion of film forming agents.

Abstract: The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.

Abstract: The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 ?m and about 75%–93% by weight of modafinil particles having diameters less than 220 ?m.

Abstract: A pharmaceutical formulation having improved bioavailability and bioequivalence includes particles of amorphous and/or crystalline atorvastatin that have a particle size (d90) less than 150 &mgr;m and a mean particle size (d50) of the atorvastatin particles that is between approximately 5 and 50 &mgr;m. The atorvastatin can be one or more of atorvastatin calcium, atorvastatin magnesium, atorvastatin aluminum, atorvastatin iron, and atorvastatin zinc. The formulations of atorvastatin can be stabilized by mixing atorvastatin with an alkali metal salt additive at between approximately 1.2% and less than 5% w/w of the formulation.